Cargando…

Protease-Activated Receptor 2 Controls Vascular Smooth Muscle Cell Proliferation in Cyclic AMP-Dependent Protein Kinase/Mitogen-Activated Protein Kinase Kinase 1/2-Dependent Manner

INTRODUCTION: Cardiovascular disorders are characterized by vascular smooth muscle (VSM) transition from a contractile to proliferative state. Protease-activated receptor 2 (PAR2) involvement in this phenotypic conversion remains unclear. We hypothesized that PAR2 controls VSM cell proliferation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Madison D., Bullock, Michael T., Johnson, Sean C., Holland, Nathan A., Vuncannon, Danielle M., Oswald, Joani Zary, Adderley, Shaquria P., Tulis, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614497/
https://www.ncbi.nlm.nih.gov/pubmed/37778342
http://dx.doi.org/10.1159/000532032
Descripción
Sumario:INTRODUCTION: Cardiovascular disorders are characterized by vascular smooth muscle (VSM) transition from a contractile to proliferative state. Protease-activated receptor 2 (PAR2) involvement in this phenotypic conversion remains unclear. We hypothesized that PAR2 controls VSM cell proliferation in phenotype-dependent manner and through specific protein kinases. METHODS: Rat clonal low (P(Lo); P3–P6) and high passage (P(Hi); P10–P15) VSM cells were established as respective models of quiescent and proliferative cells, based on reduced PKG-1 and VASP. Western blotting determined expression of cytoskeletal/contractile proteins, PAR2, and select protein kinases. DNA synthesis and cell proliferation were measured 24–72 h following PAR2 agonism (SLIGRL; 100 nM–10 μm) with/without PKA (PKI; 10 μm), MEK1/2 (PD98059; 10 μm), and PI3K (LY294002; 1 μm) blockade. RESULTS: PKG-1, VASP, SM22α, calponin, cofilin, and PAR2 were reduced in P(Hi) versus P(Lo) cells. Following PAR2 agonism, DNA synthesis and cell proliferation increased in P(Lo) cells but decreased in P(Hi) cells. Western analyses showed reduced PKA, MEK1/2, and PI3K in P(Hi) versus P(Lo) cells, and kinase blockade revealed PAR2 controls VSM cell proliferation through PKA/MEK1/2. DISCUSSION: Findings highlight PAR2 and PAR2-driven PKA/MEK1/2 in control of VSM cell growth and provide evidence for continued investigation of PAR2 in VSM pathology.